Emerging Agents in CLL

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell lymphoma.